Abstract
RET proto-oncogene encodes a receptor tyrosine kinase whose ligand is glial cell line-derived neurotrophic factor (GDNF), and its polymorphism at G691S juxtamembrane region (RETp) is a germline polymorphism. Cutaneous melanomas, particularly the desmoplastic subtype, are highly neurotropic; thus we sought to determine the frequency of RETp in cutaneous melanoma and its functional responsiveness to GDNF. RETp was assessed in 71 non-desmoplastic cutaneous melanomas (non-DMs) and 70 desmoplastic melanomas (DMs). Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity. RETp frequency was significantly higher in DMs (61%) than in non-DMs (31%, P<0.001). BRAFmt was detected in only 11% of DMs. GDNF stimulation significantly amplified cell proliferation, migration and invasion in RETp, but not in RETwt melanoma cells. GDNF stimulation of RETp cell lines enhanced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt of the RET-RAS-RAF-ERK and RET-phosphatidylinositol 3-kinase (PI3K)-Akt pathways, respectively. GDNF response of RETp cells in signal transduction and other functional studies were not affected by BRAFmt. The study demonstrates that RETp is frequently found in cutaneous melanoma, particularly desmoplastic subtypes, and responds to GDNF inducing events favorable for tumor progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Airaksinen MS, Saarma M . (2002). The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383–394.
Bounacer A, Du Villard JA, Wicker R, Caillou B, Schlumberger M, Sarasin A et al. (2002). Association of RET codon 691 polymorphism in radiation-induced human thyroid tumours with C-cell hyperplasia in peritumoural tissue. Br J Cancer 86: 1929–1936.
Busam KJ . (2005). Cutaneous desmoplastic melanoma. Adv Anat Pathol 12: 92–102.
Busam KJ, Zhao H, Coit DG, Kucukgol D, Jungbluth AA, Nobrega J et al. (2005). Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J Invest Dermatol 124: 412–418.
Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM et al. (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326–334.
Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T et al. (1994). DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9: 3025–3029.
Curtin JA, Busam K, Pinkel D, Bastian BC . (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
Davison JM, Rosenbaum E, Barrett TL, Goldenberg D, Hoque MO, Sidransky D et al. (2005). Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 103: 788–792.
Dhomen N, Marais R . (2007). New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31–39.
Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R et al. (2004). RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89: 3579–3584.
Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R et al. (1999). Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 59: 1567–1571.
Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S et al. (2008). Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 7: 3642–3653.
Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K et al. (2006). A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 66: 4443–4449.
Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117: 719–729.
Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ et al. (2007). in vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci USA 104: 6696–6701.
Hoon DS, Kuo CT, Wascher RA, Fournier P, Wang HJ, O'Day SJ . (2001). Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 117: 375–378.
Iwamoto T, Taniguchi M, Asai N, Ohkusu K, Nakashima I, Takahashi M . (1993). cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 8: 1087–1091.
Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U . (2001). The clinical behavior of desmoplastic melanoma. Am J Surg 182: 590–595.
Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M et al. (2005). The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96: 143–148.
Kondo T, Ezzat S, Asa SL . (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292–306.
Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT et al. (2005). Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23: 8057–8064.
Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F . (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130–1132.
Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm Jr MC et al. (2005). Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 23: 6739–6746.
Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G et al. (2005). The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068–1081.
Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M et al. (2006). Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 37: 199–212.
Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP et al. (2007). Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282: 29230–29240.
Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH . (1998). Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 83: 1128–1135.
Runeberg-Roos P, Saarma M . (2007). Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med 39: 572–580.
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756–759.
Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, Hines OJ et al. (2005). The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 65: 11536–11544.
Selek U, Chang EL, Hassenbusch III SJ, Shiu AS, Lang FF, Allen P et al. (2004). Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59: 1097–1106.
Shinozaki M, Fujimoto A, Morton DL, Hoon DS . (2004). Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10: 1753–1757.
Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J et al. (2007). Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 13: 2068–2074.
Stephens LA, Powell NG, Grubb J, Jeremiah SJ, Bethel JA, Demidchik EP et al. (2005). Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma. Thyroid 15: 100–104.
Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031–6039.
Takahashi M . (2001). The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12: 361–373.
Takahashi M, Buma Y, Hiai H . (1989). Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 4: 805–806.
Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H . (1988). Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3: 571–578.
Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE et al. (2005). Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24: 4721–4727.
Weber F, Eng C . (2008). Update on the molecular diagnosis of endocrine tumors: toward -omics-based personalized healthcare? J Clin Endocrinol Metab 93: 1097–1104.
Zbuk KM, Eng C . (2007). Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7: 35–45.
Acknowledgements
We thank Sandy L Nguyen and Linhda Nguyen for expert editorial assistance and Emily H Liang for technical assistance. This work was supported by the National Institutes of Health, National Cancer Institute (Project II P0 CA029605 and CA012582 grants to DH); Ruth and Martin H Weil Foundation (to DH); the Leslie and Susan Gonda Foundation (to DH) and the Melanoma Foundation of the University of Sydney, Australia (to JT, RS, RM).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Narita, N., Tanemura, A., Murali, R. et al. Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 28, 3058–3068 (2009). https://doi.org/10.1038/onc.2009.164
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.164
Keywords
This article is cited by
-
Top 10 Differential Diagnoses for Desmoplastic Melanoma
Head and Neck Pathology (2023)
-
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
Archives of Pharmacal Research (2022)
-
Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer
Journal of Experimental & Clinical Cancer Research (2020)
-
LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancer
British Journal of Cancer (2020)
-
Association of medullary sponge kidney and hyperparathyroidism with RET G691S/S904S polymorphism: a case report
Journal of Medical Case Reports (2018)